Carb Counting vs. Simplified Qualitative Meal-Size Estimation

May 15, 2025 updated by: Rabin Medical Center

Carb Counting vs. Simplified Qualitative Meal-Size Estimation- A Randomized Control Trial

The goal of this study is to compare qualitative meal-size estimation to accurate carb counting in adolescents with Type One Diabetes using all available AID (Automated Insulin Delivery) systems. We will compare glucose control parameters and patient related outcome measures between the groups. 120 children and adolescents with type 1 Diabetes who begin using AID system will be randomly assigned to one of two groups: simplified qualitative meal size estimation or accurate carb counting. The study will last 6 months, with an additional optional follow up points at 12 and 24 months.

In the first visit all patients will receive nutrition guidance from the dietitian. In the accurate carb counting group, participants will use precise carb counting to manage their meals. In the simplified qualitative meal-size estimation group, participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment. During the study, the dietitian will evaluate the insulin-to-carb ratio and meal estimation at least once in the first two weeks.

Follow-up visits will be scheduled at 4-6 weeks, 3, and 6 months after the study's initiation. At each visit participants will upload their data from their AID systems. Evaluation of their diabetes control will be made and an assessment regarding the carbohydrates calculation method. Digital questionnaires assessing diabetes distress, disordered eating behaviors, dietary regimen, and eating patterns will be provided at the beginning of the study and after 6 months, with an additional optional follow-up points that will be held at 12 and 24 months after the study's initiation.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Petah tikva, Israel, 4920235
        • Recruiting
        • Schneider Children's Medical Center
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. T1D- diagnosed
  2. Age 6-18 years
  3. Treated with insulin (multiple daily injections or pump) and intending to initiate treatment with AID systems

Exclusion Criteria:

  1. Non-T1D
  2. Unstable medical conditions (other than diabetes) that may impact weight or diabetes management (as severe psychiatric disorders, various syndromes)
  3. Use of medications that may impact weight or diabetes management (as use of steroids for an extended period of time. use of GLP-1)
  4. Inability to understand the information, material and questionnaires of the study -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Accurate carb counting
Participants will use precise carb counting to manage their meals
Participants will use precise carb counting to manage their meals
Experimental: Simplified qualitative meal-size estimation
Participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian assessment.
participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage of time in target range (70-18mg/dl)
Time Frame: Screening, after 4-6 weeks, after 3 months and after 6 months
Screening, after 4-6 weeks, after 3 months and after 6 months
Hemoglobin A1C
Time Frame: Screening, after 4-6 weeks, after 3 months and after 6 months
Screening, after 4-6 weeks, after 3 months and after 6 months
Percentage Continuous glucose monitoting usage
Time Frame: Screening, after 4-6 weeks, after 3 months and after 6 months
Screening, after 4-6 weeks, after 3 months and after 6 months
Number of Episodes of severe hypoglycemia
Time Frame: Screening, after 4-6 weeks, after 3 months and after 6 months
Screening, after 4-6 weeks, after 3 months and after 6 months
Number of episodes of Diabetic Ketoacidosis
Time Frame: Screening, after 4-6 weeks, after 3 months and after 6 months
Screening, after 4-6 weeks, after 3 months and after 6 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Total daily insulin dose
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
at screening, after 4-6 weeks, after 3 months and after 6 months.
basal insulin dose
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
at screening, after 4-6 weeks, after 3 months and after 6 months.
Number of manual boluses per day
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
at screening, after 4-6 weeks, after 3 months and after 6 months.
Number of announced meals per day
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
at screening, after 4-6 weeks, after 3 months and after 6 months.
Daily carbohydrates input
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
at screening, after 4-6 weeks, after 3 months and after 6 months.
Percentage of automated insulin delivery use
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
at screening, after 4-6 weeks, after 3 months and after 6 months.
Number of automated insulin delivery exits per week
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
at screening, after 4-6 weeks, after 3 months and after 6 months.
Percentage of automated boluses
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
at screening, after 4-6 weeks, after 3 months and after 6 months.
Score of Diabetes distress according to questionnaire
Time Frame: At screening and after 6 months
At screening and after 6 months
Score of Disordered eating behaviors according to quesiotnnaire
Time Frame: At screening and after 6 months
At screening and after 6 months
Score of Dietary regimen according to questionnaire
Time Frame: At screening and after 6 months
At screening and after 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 15, 2024

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

December 15, 2027

Study Registration Dates

First Submitted

October 21, 2024

First Submitted That Met QC Criteria

November 12, 2024

First Posted (Actual)

November 13, 2024

Study Record Updates

Last Update Posted (Estimated)

May 20, 2025

Last Update Submitted That Met QC Criteria

May 15, 2025

Last Verified

October 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 1 Diabetes Mellitus

Clinical Trials on accurate carb counting

Subscribe